COSCIENS Biopharma Inc.
CSCIF
$2.09
-$0.16-7.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.01% | 32.65% | 26.10% | 45.70% | -16.96% |
| Total Depreciation and Amortization | 0.70% | 0.00% | -11.69% | -17.09% | -18.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.21% | -124.23% | 218.70% | -95.24% | 59.43% |
| Change in Net Operating Assets | -53.84% | 139.22% | -282.74% | 75.99% | 118.28% |
| Cash from Operations | -117.46% | 84.80% | -136.54% | 37.31% | 61.45% |
| Capital Expenditure | -- | -- | 92.03% | -99.03% | -135.88% |
| Sale of Property, Plant, and Equipment | 5,875.00% | 300.00% | -75.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 42.86% | -103.27% |
| Cash from Investing | 4,925.00% | 108.33% | 92.20% | -94.62% | -480.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 82.35% | -30.77% | 67.50% | -83.49% | 4.39% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -25.68% |
| Cash from Financing | 82.35% | 20.56% | 46.50% | 0.99% | -7.45% |
| Foreign Exchange rate Adjustments | 228.85% | -129.38% | 195.00% | 168.18% | -212.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -50.43% | 81.72% | -67.93% | 26.91% | 53.82% |